- Home
- MBBC vs IGC Comparison
MBBC vs IGC Comparison
Compare MBBC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- IGC
- Stock Information
- Founded
- MBBC 1902
- IGC 2005
- Country
- MBBC United States
- IGC United States
- Employees
- MBBC N/A
- IGC N/A
- Industry
- MBBC Banks
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- IGC Health Care
- Exchange
- MBBC Nasdaq
- IGC Nasdaq
- Market Cap
- MBBC 22.1M
- IGC 20.2M
- IPO Year
- MBBC N/A
- IGC N/A
- Fundamental
- Price
- MBBC $10.05
- IGC $0.30
- Analyst Decision
- MBBC
- IGC Strong Buy
- Analyst Count
- MBBC 0
- IGC 2
- Target Price
- MBBC N/A
- IGC $3.88
- AVG Volume (30 Days)
- MBBC 13.3K
- IGC 190.2K
- Earning Date
- MBBC 05-12-2025
- IGC 06-23-2025
- Dividend Yield
- MBBC N/A
- IGC N/A
- EPS Growth
- MBBC N/A
- IGC N/A
- EPS
- MBBC N/A
- IGC N/A
- Revenue
- MBBC $6,554,694.00
- IGC $1,236,000.00
- Revenue This Year
- MBBC N/A
- IGC N/A
- Revenue Next Year
- MBBC N/A
- IGC $16.45
- P/E Ratio
- MBBC N/A
- IGC N/A
- Revenue Growth
- MBBC N/A
- IGC 1.65
- 52 Week Low
- MBBC $5.83
- IGC $0.25
- 52 Week High
- MBBC $12.00
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- IGC 51.47
- Support Level
- MBBC N/A
- IGC $0.28
- Resistance Level
- MBBC N/A
- IGC $0.32
- Average True Range (ATR)
- MBBC 0.00
- IGC 0.01
- MACD
- MBBC 0.00
- IGC 0.00
- Stochastic Oscillator
- MBBC 0.00
- IGC 55.80
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.